| pubmed-article:18525302 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18525302 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:18525302 | lifeskim:mentions | umls-concept:C0278678 | lld:lifeskim |
| pubmed-article:18525302 | lifeskim:mentions | umls-concept:C1144149 | lld:lifeskim |
| pubmed-article:18525302 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:18525302 | pubmed:dateCreated | 2008-6-5 | lld:pubmed |
| pubmed-article:18525302 | pubmed:abstractText | Treatments for refractory metastatic renal cell cancer (RCC) are limited. Oral lenalidomide, a thalidomide-based drug having enhanced immunomodulatory and antiangiogenic properties and reduced toxicity, was evaluated for safety and efficacy in this setting. | lld:pubmed |
| pubmed-article:18525302 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18525302 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18525302 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18525302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18525302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18525302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18525302 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18525302 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:18525302 | pubmed:issn | 1537-453X | lld:pubmed |
| pubmed-article:18525302 | pubmed:author | pubmed-author:AmatoRobert... | lld:pubmed |
| pubmed-article:18525302 | pubmed:author | pubmed-author:MuhammadKhanK | lld:pubmed |
| pubmed-article:18525302 | pubmed:author | pubmed-author:SaxenaSomyata... | lld:pubmed |
| pubmed-article:18525302 | pubmed:author | pubmed-author:Hernandez-McC... | lld:pubmed |
| pubmed-article:18525302 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18525302 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:18525302 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18525302 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18525302 | pubmed:pagination | 244-9 | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:meshHeading | pubmed-meshheading:18525302... | lld:pubmed |
| pubmed-article:18525302 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18525302 | pubmed:articleTitle | Lenalidomide therapy for metastatic renal cell carcinoma. | lld:pubmed |
| pubmed-article:18525302 | pubmed:affiliation | Genitourinary Oncology Program, Methodist Hospital Research Institute, Houston, TX 77030, USA. ramato@tmh.tmc.edu | lld:pubmed |
| pubmed-article:18525302 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18525302 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18525302 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18525302 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18525302 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18525302 | lld:pubmed |
